Mark E. Dunlap, MD Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio
Ross C. Peterson, MD University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio
Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail med3@po.cwru.edu
Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.
This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTAlthough angiotensin-converting enzyme (ACE) inhibitors decrease mortality in heart failure, they incompletely suppress angiotensin II with long-term therapy. Since angiotensin receptor blockers (ARBs) block the biologic effects of angiotensin II more completely than ACE inhibitors, they could be beneficial in the treatment of heart failure.
